Arena Pharma (ARNA) to Present Data from the Phase 2b ADVISE Trial - Late-Breaker at Revolutionizing Atopic Dermatitis Conference

December 11, 2020 9:03 AM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from the Phase 2b ADVISE trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderate-to-severe atopic dermatitis (AD), will be presented at the Revolutionizing Atopic Dermatitis (RAD) 2020 Virtual Conference.

"I am pleased to present the topline results from the ADVISE Phase 2 trial which support the rationale for etrasimod as a potential oral, once-daily therapy with a novel mechanism of action for the treatment of atopic dermatitis. I look forward to seeing the advancement of etrasimod to the next phase of clinical development," stated Robert Bissonnette, MD, FRCPC, Founder and CEO, Innovaderm Research. "There is a significant unmet clinical need for the development of novel oral therapeutic options for atopic dermatitis patients."

Title: Results from ADVISE: a randomized, double-blind, placebo-controlled Phase 2 study of etrasimod, an oral, selective, sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitisPresenter: Dr. Robert Bissonnette Authors: Jonathan Silverberg, Robert Bissonnette, Leon Kircik, Dedee Murrell, Andrew Selfridge, Gurpreet Ahluwalia, Kris Liu, Emma Guttman-YasskyDate/Time: 8:50 – 8:57 AM ET, Monday, December 14, 2020Session: Late-Breaking Research Session

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA